In two major clinical trials (SHARP and phase III of AP), sorafenib frequently developed resistance during treatment, which may be related to CD11b+Gr1+ myeloid cell infiltration into tumor tissues [128]. The gene discussed is ITGAM; the disease is neoplasm.